Compare AU
Compare DRUG vs. BANK
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are DRUG and BANK. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | BANK | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 59 | 15 |
Median incremental investment | $920.50 | $995.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,988.48 | $1,001.00 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | BANK | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | BANK.AX was created on 2024-07-22 by Global X. The fund's investment portfolio concentrates primarily on investment grade fixed income. The investment objective of the Fund is to provide investors a return (before fees and expenses) that tracks the performance of the Solactive Australian Bank Credit Index, a published index, by holding a portfolio of Bonds and Hybrid Securities that may comprise all or a representation of the securities comprising the Index. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Global X Australian Bank Credit ETF (100 %) |
Top 3 industries | Other (75.15 %) Communication Services (33.53 %) Health Care (24.75 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.57 % | 0.25 % |
Key Summary
DRUG | BANK | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive Australian Bank Credit Index - AUD - Benchmark TR Gross |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.25 % |
Price | $8.25 | $9.99 |
Size | $183.750 million | $41.258 million |
10Y return | N/A | N/A |
Annual distribution/ dividend yield (5Y) | 1.89 % | 0.62 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 23/07/2024 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | BANK | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 59 | 15 |
Median incremental investment | $920.50 | $995.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,988.48 | $1,001.00 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | BANK | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | BANK |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |